CLINICAL TRIAL PATIENT TECHNOLOGY INSIGHTS
-
The Site Perspective: Why Ambient AI Is The Missing Link In Clinical Trial Data Integrity
Discover how AI ambient listening has changed the way Mikel Daniels, DPM, MBA, and his team conduct clinical research at WeTreatFeet Podiatry.
-
Penetration Testing In Healthcare: Common Vulnerabilities And Programs To Address Them
Explore some of the common pitfalls witnessed in healthcare environments, as well as guidance for implementing a penetration testing program.
ECOA RESOURCES
-
Learn how an eCOA tool can provide patients a chance to be heard while giving sponsors quantitative and qualitative data to track the efficacy of a treatment.
-
Explore why the integration of etechnologies is critical in the modernization and optimization of clinical trials, and how the right partner will ensure studies are more efficient, reliable, and inclusive.
-
Consider these three aspects when choosing an electronic Clinical Outcome Assessments (eCOA) provider and preparing to set up an eCOA clinical trial.
ECONSENT RESOURCES
-
Scott Askin paints the picture of why Novartis, determined to improve the patient experience, has begun to deploy eConsent, and what they’ve learned along the way.
-
Explore why the integration of etechnologies is critical in the modernization and optimization of clinical trials, and how the right partner will ensure studies are more efficient, reliable, and inclusive.
-
In this on-demand webinar attendees will learn about the common misconceptions surrounding eConsent, as well as the benefits they can realize through a digitally-enabled approach.
EPRO RESOURCES
-
Unlock the potential of electronic Patient Reported Outcomes (ePRO) in your clinical research by implementing these essential best practices for success.
-
As actigraphy continues to advance, explore how improvements in device comfort and usability will enhance patient compliance, further optimizing its pivotal role in clinical research across various therapeutic domains.
-
In this blog, explore how the approach to PROs needs to be reconsidered, given increasing regulations and trial scrutiny, the clinical need for patient-reported outcomes, and the ability to drive costs down and move off paper.